Portugal News

Chinese artist Ai Weiwei, now residing in Portugal's Alentejo region, spoke candidly about his life and art during a recent interview with EL PAÍS. At 67, Weiwei, who has become one of the world's most sought-after artists, has purchased his first home and expresses a dispassionate view on wealth, stating that “money... is very poisonous. You’re only worth as much as your work.” His new 17-acre property is a significant investment; in China, property ownership is scarce and he refers to this ownership as “like a miracle.” Weiwei's background is steeped in political turmoil; he was imprisoned for 81 days in 2011 and has faced constant surveillance from the Chinese government. He uses his art as a platform for political expression, aiming to give voice to the marginalized. His current exhibition, titled "Don Quixote," confronts themes of identity and societal absurdities as he continues to challenge oppressive structures through his work. Weiwei commented, "I act as a loudspeaker for thousands of people who aren’t given a voice,” reinforcing his role as both an artist and an outspoken critic.

Prince Karim Aga Khan IV, the spiritual leader of the Ismaili Muslim community and a prominent philanthropist, has died at the age of 88 in Portugal, surrounded by family, according to a statement from the Aga Khan Foundation. Known as a direct descendant of the Prophet Muhammad, the Aga Khan became leader of the Ismailis at just 20 years old while still studying at Harvard University. Widely respected for his philanthropic efforts, the Aga Khan developed a vast network focused on health care, education, and rural economic development. He was known for his contributions to healthcare in several countries, including Bangladesh, Tajikistan, and Afghanistan. His work also included the establishment of architecture programs at prominent institutions such as MIT and Harvard, and the restoration of historic Islamic structures. The Ismaili community, which has expanded from its origins in India to significant numbers in East Africa, Central and South Asia, is anticipated to announce his successor in the coming days, as stated by officials closely associated with the Aga Khan's legacy.

Prince Karim Aga Khan IV, revered by his followers as a direct descendant of the Prophet Muhammad, has passed away at the age of 88 in Portugal. The Aga Khan, who became the spiritual leader of millions of Ismaili Muslims at just 20 years old, was known for his extensive philanthropic work through the Aga Khan Development Network, focusing on health care, education, and economic development in underserved regions. His death was announced by the Aga Khan Foundation and the Ismaili community, which stated that details regarding his successor will be revealed later. Aga Khan IV was educated at Harvard and took on leadership following his grandfather's unexpected decision to pass over his father. He was instrumental in building a network of hospitals and schools in countries like Afghanistan and Bangladesh, significantly impacting local economies. Beyond his spiritual role, he balanced business and philanthropy, accumulating a vast financial empire. The Aga Khan was also known for promoting Islamic culture and fostering dialogue between Muslim societies and the West. He is survived by three sons and a daughter.

Aga Khan, the billionaire philanthropist and spiritual leader of the Ismaili Muslims, has died at age 88, as confirmed by his charity, the Aga Khan Development Network. According to a statement shared on social media, Prince Karim Aga Khan "passed away peacefully" in Lisbon, Portugal, amidst family. Born in Switzerland, he held British citizenship and resided in France. The Aga Khan served as the 49th hereditary imam of the Ismaili Muslims, a sect that boasts a global population of approximately 15 million members. King Charles III, reportedly a personal friend of the Aga Khan's and deeply saddened by his death, has offered private condolences to his family. Throughout his lifetime, the Aga Khan's charities have spearheaded numerous initiatives in healthcare, education, and culture, especially in developing nations. His estimated fortune of $1 billion in 2008 was amplified by various business ventures, including horse-breeding. He is particularly renowned for breeding the illustrious racehorse, Shergar. The Aga Khan Development Network has expressed its condolences to his family and the Ismaili community worldwide, asserting a commitment to continuing his legacy of service across religious and cultural divides.

In the summer of 2001, the small island of São Miguel in the Azores, Portugal, was engulfed in chaos when hundreds of packages of uncut cocaine began washing up on its shores. The situation spiraled after teenagers, mistaking the white powder for chalk, unknowingly introduced the drug into their community. The event marked a significant turning point for the island, which had previously experienced little drug-related crime. Initial reports indicated that locals discovered around half a metric tonne of cocaine worth approximately £40 million. Many individuals took advantage of the influx, collecting and selling the drug at alarmingly low prices, which contributed to a rapid rise in addiction among the island's youth. Inspector Jose Lopes, who worked on the case, noted that cocaine was sold in "beer glasses for €5 each," significantly undermining its value. The influx of cocaine was linked to an Italian smuggler named Antonino Quinci, who had diverted to São Miguel due to a storm while attempting to transport the drug from Venezuela to Spain. He originally concealed the cocaine in a cave; however, the storm caused many of the packages to surface and beach themselves. As addiction rates soared, with reports of children as young as 12 using cocaine, health services were overwhelmed. Within a month, overdose cases began to appear, leading to avoidable deaths within the community. The initial quiet nature of São Miguel was rapidly replaced by a vibrant but destructive nightlife centered around drug use. Despite attempts to address the problem and the decriminalization of all drugs in Portugal in July 2001, the impacts of this "cocaine wave" were profound and long-lasting. Local resources for rehabilitation and mental health support have remained insufficient, leading to the persistence of addiction in the area. Current reports indicate that the island is also now grappling with newer synthetic drugs, leading to an ongoing cycle of substance abuse among residents. The legacy of the summer of 2001 continues to cast a long shadow over São Miguel, fundamentally altering its social fabric.

In June 2001, the tranquil island of São Miguel, part of the Azores archipelago owned by Portugal, was thrust into chaos when hundreds of packages of uncut cocaine washed ashore. The drug, discovered by local youths while foraging on the beach, led to a surge of usage that would leave a profound impact on the community. Initially, residents stumbled upon packets the size of hardback books, leading to police seizures totaling half a metric tonne of cocaine valued at approximately £40 million. With the abundance of the drug, prices plummeted, resulting in alarming patterns of usage among local youth. Reports describe children as young as 12 trying cocaine and the rise of novice dealers driving around with sports bags filled with the drug. The smuggler behind this crisis, Antonino Quinci, a 44-year-old Italian, sought refuge on the island after encountering issues with his yacht. His decision to hide his remaining cocaine cargo in a cave inadvertently resulted in a catastrophic influx of drugs onto the streets. The situation spiraled out of control, with even long-time residents getting ensnared in addiction. Health facilities struggled to cope with an unexpectedly high influx of patients suffering from addiction-related conditions, marking a tragic transformation for the island’s previously stable community. Over two decades later, locals still grapple with the lingering effects of this event, and drug abuse remains a pervasive issue, further complicated by the emergence of newer synthetic drugs. As the region strives to recover, the lasting scars of Quinci's operation serve as a reminder of the dangerous intersection between drug trafficking and local economies. The story of São Miguel prompts urgent calls for better drug treatment resources and preventative measures to combat similar crises.

Researchers at the International Iberian Nanotechnology Laboratory in Braga, Portugal, have developed a groundbreaking brain-on-a-chip technology aimed at enhancing treatments for neurological disorders, particularly Alzheimer's disease. Funded by the European Union, this advanced microchip mimics the human brain's complex functions and has the potential to significantly improve the effectiveness of new therapeutic approaches. The unique device, created as part of the two-year BrainChip4MED project, is designed to overcome the challenges posed by the blood-brain barrier, a protective membrane that prevents many drugs from effectively reaching the brain. By recreating this barrier using bioorganic materials, researchers can more accurately test how medications penetrate the brain, thereby addressing a critical obstacle in developing new Alzheimer's drugs. Currently, only four drugs are commercially available for Alzheimer's, none of which address the root causes of the disease. The brain-on-a-chip technology not only offers a more ethical alternative to animal testing but also allows for real-time monitoring of drug efficacy in a controlled environment. The research team, led by Dr. Raquel Rodrigues, stresses the importance of finding new treatments to combat Alzheimer's, which affects approximately 165 million Europeans. The innovative chip will undergo further testing before it can be utilized in human medicine, but the researchers remain optimistic about its potential to revolutionize neurological research.

Researchers from the International Iberian Nanotechnology Laboratory (INL) in Portugal have developed an innovative brain-on-a-chip device that aims to transform the treatment of Alzheimer's disease and other neurological disorders. Funded by the European Union, this groundbreaking project, known as BrainChip4MED, focuses on enhancing the efficacy of drug development by simulating human brainfunction on a microchip. Dr. Raquel Rodrigues, a chemical and biological engineer, emphasized the complexity of the brain and the necessity for advanced monitoring techniques. The chip, which is roughly the size of a thumbnail, employs microfluidic technology to analyze tiny quantities of nanotherapeutics simultaneously and addresses the challenge of penetrating the blood-brain barrier, a protective membrane that limits the effectiveness of many drugs. Traditional drug-testing methods often rely on animal models, which can differ significantly from human biology, leading to high failure rates in drug development. The researchers believe their device, which utilizes a bio-organic membrane that closely mimics the blood-brain barrier, could significantly reduce these shortcomings. By allowing researchers to observe how potential medications interact with the brain barrier without human trials, this new technology offers a more ethical and potentially more accurate approach to drug development. Although the prototype is complete, it requires additional refinement and rigorous testing before it can be applied in human medicine. The ongoing research could have far-reaching impacts, as an estimated 165 million Europeans suffer from brain disorders, with the financial burden on healthcare systems projected to rise dramatically in the coming years. Dr. Manuel Bañobre-López, who oversees the Nanomedicine Research Group at INL, highlighted that this technological advancement represents a vital step forward in combating Alzheimer's disease.

Researchers at the International Iberian Nanotechnology Laboratory in Braga, Portugal, have developed a groundbreaking brain-on-a-chip technology that could revolutionize the development of treatments for Alzheimer's disease and other neurological disorders. Funded by the European Union, the project, known as BrainChip4MED, aims to create more effective drugs by mimicking the human brain's functionality in a compact microchip format. Dr. Raquel Rodrigues, one of the lead researchers, emphasized the complexity of the brain and the need for advanced monitoring systems to enhance understanding and treatment of neurological conditions. The team has crafted a thumbnail-sized chip that utilizes microfluidics technology to simulate brain processes and screen new nanotherapeutics in real time. One of the primary objectives of this innovative chip is to overcome the significant barrier presented by the blood-brain barrier, which prevents many drugs from effectively reaching their targets in the brain. Current Alzheimer’s medications only alleviate symptoms, as no effective treatments penetrate the barrier well. By recreating the blood-brain barrier using bioorganic materials on the chip, researchers can better evaluate the effectiveness of potential drugs before human trials. While the prototype of the brain-on-a-chip is complete, further refinement and rigorous testing are required before it can be utilized for human medicine. Dr. Manuel Bañobre-López, leader of the Nanomedicine Research Group at INL, noted that despite the challenges, the development marks a significant advancement in the field of neurotherapeutics. With approximately 165 million Europeans estimated to be living with brain disorders, the potential impact of this technology could be profound, addressing critical health challenges posed by diseases such as Alzheimer’s and Parkinson’s.

Researchers at the International Iberian Nanotechnology Laboratory (INL) in Braga, Portugal, have developed a groundbreaking brain-on-a-chip technology aimed at enhancing treatments for Alzheimer's disease and other neurological disorders. Dr. Raquel Rodrigues, a chemical and biological engineer at INL, highlighted the complexity of the human brain and the necessity for advanced tools to monitor brain activity and improve drug development. The technology, funded by the European Union, emerged from a two-year research project, BrainChip4MED, which wrapped up in February 2024. The resulting brain-emulating microchip, resembling a small computer chip, utilizes a combination of chemistry, biology, and engineering to create a micro-biosensor system. This innovative chip implements microfluidics, allowing researchers to test multiple samples and analyze tiny quantities of substances, ultimately reducing costs associated with drug testing. A significant challenge in treating neurological disorders is the blood-brain barrier, a protective membrane that limits drug access to the brain. By recreating this barrier using bioorganic material on the chip, researchers can assess how well potential treatments penetrate this crucial barrier. Current Alzheimer’s medications only address symptoms rather than the disease itself, primarily due to the financial risks pharmaceutical companies face when developing drugs that may not cross the blood-brain barrier. Dr. Manuel Bañobre-López, INL's Nanomedicine Research Group leader, noted that while the prototype is ready, additional refinement and rigorous testing are essential before it can be utilized in human clinical trials. Given that around 165 million Europeans live with brain disorders, and with associated healthcare costs expected to rise, this innovative technology represents a significant step forward in addressing these pressing health challenges. The development of the brain-on-a-chip is expected to revolutionize the way neurological therapies are developed, moving away from traditional animal testing methods towards more ethical and effective alternatives.

Researchers have developed a groundbreaking brain-on-a-chip technology that could revolutionize treatment for Alzheimer's disease and other neurological disorders. Funded by the EU, the project led by Dr. Raquel Rodrigues at the International Iberian Nanotechnology Laboratory in Braga, Portugal, aims to better understand the complex workings of the human brain. The microchip—roughly the size of a thumbnail—simulates brain function through an intricate system that combines chemistry, biology, and engineering. The chip employs microfluidic technology to analyze small quantities of samples concurrently, significantly lowering testing costs. One of the key challenges addressed by this technology is the blood-brain barrier, which restricts most drugs from reaching the brain. The team recreated this barrier on the chip using bioorganic materials, offering a more accurate model than previously used polymeric systems. The goal is to test how well new medicines can penetrate this barrier, potentially changing the development landscape for neurological drugs. The researchers emphasize the significance of this advancement, as existing Alzheimer's treatments only manage symptoms rather than targeting the disease itself. Current testing methods often rely on animal models, which can be problematic due to biological differences with humans. The project, known as BrainChip4MED, concluded in February 2024 but requires further refinement and testing before the technology can be used for human applications. Nevertheless, the team is optimistic that this microchip can be transformed into a vital tool in the fight against Alzheimer’s and other severe brain disorders, which impact millions of people across Europe.